NeurologyOnline.net

Neurology Xagena

Xagena Mappa
Medical Meeting
Mediexplorer.it
Gastrobase.it

Search results for "Glatiramer"

Clinical research data, published in the journal Multiple Sclerosis, provided evidence that Copaxone ( Glatiramer ) may offer protection from axonal injury and induced neuronal metabolic recovery in p ...


Adding Salbutamol ( Albuterol; Ventolin ), a compound commonly used to treat asthma and other respiratory diseases, to an existing treatment for patients with multiple sclerosis appears to improve cli ...


Researchers from the National Network of Pediatric MS Centers of Excellence, in the first retrospective study of the response of children with multiple sclerosis to standard, or first-line, therapies, ...


Disease-modifying therapies ( DMTs ) for multiple sclerosis aim to specifically reduce inflammation in relapsing multiple sclerosis and promote neuroprotection and neurorepair in progressive multiple ...


The results from the Lemtrada ( Alemtuzumab ) CARE-MS I and CARE-MS II pivotal studies in patients with relapsing-remitting multiple sclerosis were published in The Lancet.In CARE-MS I and CARE-MS II, ...


Data from the phase III GALA ( Glatiramer Acetate Low-Frequency Administration ) trial were presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis ( ...


More than 80% of individuals with multiple sclerosis ( MS ) experience a relapsing-remitting disease course. Approximately 10 years after disease onset, an estimated 50% of individuals with relapsing- ...


In patients with relapsing–remitting multiple sclerosis ( RRMS ), a scoring system based on new magnetic resonance imaging ( MRI ) active lesions, relapses and sustained disability progression after a ...


ENDORSE is an ongoing, 5-year, dose-blind extension of the phase 3 DEFINE and CONFIRM studies evaluating the efficacy and safety of delayed-release Dimethyl fumarate ( DMF ) in relapsing-remitting mul ...


NARCOMS has provided a registry of 37,000+ patients with multiple sclerosi. Disability, measured by Patient Determined Disease Steps ( PDDS ), was retrospectively compared between NARCOMS participants ...


Five-year results from the ENDORSE phase 3 extension study have shown Dimethyl fumarate ( Tecfidera ) provides strong and sustained efficacy in a broad range of people living with relapsing-remitting ...


The purpose was to report the effects of delayed-release Dimethyl fumarate ( DMF; also known as gastro-resistant DMF ) on the number of relapses requiring intravenous ( IV ) steroids and multiple scle ...


The phase 3 ASCEND study investigating Natalizumab ( Tysabri ) in the treatment of secondary progressive multiple sclerosis ( SPMS ) did not achieve its primary and secondary endpoints. During the stu ...


Multiple sclerosis ( MS ) is a chronic disabling disease of the central nervous system ( CNS ), affecting more than 2 million people worldwide. The disease usually starts in early adulthood, but the ...


There are increasing data that delaying starting disease-modifying drugs and/or routinely stopping all disease-modifying drugs prepregnancy or immediately postconception is associated with increased r ...